Treatment and access to treatment in low and middle income countries
description
Transcript of Treatment and access to treatment in low and middle income countries
Treatment and access to treatment in low and middle income
countries
Adeeba KamarulzamanUniversity of Malaya
Kuala Lumpur, Malaysia
ANRS-NIDA Joint Satellite
Drug Use and HIV and HCV Infection: The Challenge and The Potential Solutions
Global Estimates of HIV-Viral Hepatitis Coinfection
HCV Prevalence in Asia, Africa and Eastern Europe
1Madhava V. Lancet 2002. 2Nelson P, Lancet 2011. 3Ba I, ICASA 20127
Dakar area – UDSEN study3
-est.size IVDUs: 1324- P(HIV): 5,2%- P (HCV): 23,3%
Bulgaria
Greece Ita
ly
Cyprus
Austria
Romania
0
20
40
60
80
20052010
ThailandNepal
PakistanMacau
MyanmarIndonesia
VietnamPhillipinesCambodia
ChinaMalaysia
JapanKorea (Republic of)
AustraliaBangladesh
SingaporeIndia
TaiwanAfghanistan
Maldives
0 10 20 30 40 50 60 70 80 90 100
HCV Ab prevalence among people who inject drugs is high
Source: Nelson PK et al. Global epidemiology of hepatitis B and hepatitis C and people who inject drugs. Lancet 2011: 278:571
Estimating HIV Prevalence in Malaysia
Method
Multi-parameter evidence synthesis methods were applied to combine all available relevant data sources
Results • An estimated 454,000 (95% [CrI]: 392,000 to 535,000) HCV Ab
positive individuals were living in Malaysia in 2009• 2.5% of the adult population• Route of probable transmission - active or a previous history of
IDU• Females represented 1% (95% CrI: 0.6 to 1.4%) of all HCV
infections, 92% (95% CrI: 88 to 95%) were attributable to non-drug injecting routes of transmission SA McDonald, A Kamarulzaman et al. Submitted for publication
Liver-related death: Leading cause of death in HIV-HCV patients
Unknown
Other
Suicide
Overdose
lung
non HIV infections
Cardiovscular
HIV
Cancer (non HIV non HCV)
Liver (including HCC)
0 5 10 15 20 25 30 35 40
43 %
12 %
8 %
5 %
4 %
4 %
4 %
2 %
6 %
7 %
Decompensated cirrhosisHCCPost-transplantation
Cirrhotic Patients: > 50% deaths related to HCVNon cirrhotic patients : 60% deaths non related to HCV nor HIV
1HSogni P. Conference on French HIV-HCV Consensus Guidelines, 2012
13
% o
f pati
ents
with
sus
tain
ed v
irolo
gica
l res
pons
e (S
VR)
IFN
24 W
70
50
30
20
10
60
40
IFN
48 W
IFN+RBV
24 W
IFN+RBV
48 W
PEG-IFN+RBV
48 W
0
80
90
IFN = Interferon-αPEG-INF = Peg-Interferon-αRBV = RibavirinPEG = PEG-IFN-α
2002
2011
1999
2014
PEG-IFN+RBV
+new PI Telaprevir
Or Boceprevir
INF-free regimens12 weeks
? 95-100% SVR
New Anti HCV Therapy
• PHOTON 1 & 2 – Sofosbuvir + RBV• ERADICATE Study - Sofosbuvir +
Ledipasvir• C-WORTHY Trial - PI MK-5172 + NS5A
inhibitor MK-8742, with or without ribavirin• TURQUOISE 1 –
ABT-450/r/Ombitasvir,Dasabuvir + RBV
Estimated proportion of persons with chronic HCV receiving treatment in selected European countries in 2010
Source: Razavi et al J Hepatol. 2013;58(Suppl 1):S22–3
Treatment coverage remains very low, even in high-income
countries
Total population (2012)
Estimated number PLHIV (all ages, 2012)
Reported number of adults receiving ART
(2012)
Coverage (range of
uncertaintyA)
Cambodia 14,864,64 76,000 44,318 82% [60%->95%]
China 1,350,695,000 780,000 151,519 Not available
India 1,236,686,732 2,100,000
570,620 51% [44%-57%]
Indonesia 246,864,191 610,000
29,960 18% [12-25%]
Malaysia 29,239,927 82,000 14,594
41% [32%-52%]
Myanmar 52,797,319 200,000
49,676 46% [41%-51%]
Nepal 27,474,377 49,000
7,168 33% [28%-40%]
PNG 7,167,010 25,000 11,042 84% [73%->95%]
Thailand 66,785,001 440,000 232,816
76% [71%-80%]
Vietnam 88,772,900 260,000 68,883 58% [19%->95%]
Estimated number of PLHIV and of people on ART in 10 countries in Asia-Pacific, 2012
A The range of uncertainty reflects the degree of uncertainty associated with estimates and defines the boundaries within which the actual numbers lie (see http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/20131118_Methodology.pdf, accessed 1 June 2014). Source: UNAIDS 2013, World Bank 2012)PLHIV=People living with HIV
Number of people who inject drugs (PWID) on ART per 100 HIV+ PWID
Source: Beyrer, Baral
Less than 25% of HIV+ PWID are on ART in Asia and Pacific < 25
25-75
> 75
PWID present but ART program data not available
No PWID reportedPWID=people who inject drugs
Multiple Barriers at Multiple Steps of the Continuum of Care
Adapted from G. Matthews
Barriers to HCV Treatment in Low/Middle Income Countries
• Lack of Awareness• Late Diagnosis• Poor Treatment Literacy• Multiple Comorbidities – TB• Lack of Access to OST• Limited Range of ARVs
Treating HCV in Resource-Poor Settings CID 2012:54 (15 May) d 1465
Lessons from HIV
• Reducing Cost of Treatment• Simplifying Model of Care• Service Integration• Task Shifting• Surveillance, Evaluation and Research• Patient & Community Engagement• Political and Financial Commitment
Overcoming Provider Barriers
Easier assessment of the infection and the liver disease2
-Dry-blood spots (HCV viral load quantification/genotyping)- Portable Fibroscan (Echosens)- Portable sonography
Rapid Testing1
- Point-of-care tests- Salivary rapid testing
1Yaari A, J Viral Methods 2006. 2Tuaillon E, Hepatology 2010
47Mostly unavailable in RLS
Overcoming the Cost Barrier
http://www.medicinespatentpool.org
48
History of HIV
Viral Hepatitis
Acknowledgements
• Karine Lacombe, Inserm• Ying-Ru Lo, WPRO WHO• Joe Sasadeusz, Alfred Hospital, Melbourne